Acquired resistance to cabergoline: Progression from initially responsive micro to macroprolactinoma

Pituitary

Volumn 13, Issue 4, 2010, Pages 380-382

  Alberiche Ruano, M ^a   Boronat Cortes M ^a   Ojeda Pino, A ^a   Rodriguez Perez, C ^a   Gracia Nunez M ^a   Marrero Arencibia, D ^a   Novoa Mogollon F J ^a  

^a HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DEXAMETHASONE; LUTEINIZING HORMONE; PROLACTIN;

ADULT; ANAMNESIS; ARTICLE; BLURRED VISION; CANCER GROWTH; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GALACTORRHEA; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS APOPLEXY; LUTEINIZING HORMONE BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RECURRENT DISEASE; TRANSSPHENOIDAL SURGERY; TUMOR BLEEDING; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ERGOLINES; FEMALE; HUMANS; PROLACTINOMA;

EID: 78049242881     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-010-0237-4     Document Type: Article

References (11)

1. Behan LA, Draman MS, Moran C, King T, Crowley RK, O'Sullivan EP et al (2009) Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary Feb 4 (Epub ahead of print)
2. A Di Sarno ML Landi P Cappabianca F Di Salle FW Rossi R Pivonello, et al. 2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy J Clin Endocrinol Met 86 5256 5261 1:CAS:528:DC%2BD3MXos1KqsL4%3D 10.1210/jc.86.11.5256 (Pubitemid 33070245)
3. A Colao G Vitale P Cappabianca F Briganti A Ciccarelli M De Rosa, et al. 2004 Outcome of cabergoline treatment in men with prolactinoma: effects of a 24. month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis J Clin Endocrinol Met 89 1704 1711 1:CAS:528:DC%2BD2cXjt1elsbc%3D 10.1210/jc.2003-030979 (Pubitemid 38507923)
4. A Olafsdottir J Schlecht 2006 Management of resistant prolactinomas Nat Clin Pract Endocrinol Metab 2 552 561 1:CAS:528:DC%2BD28XhtFKqtb%2FF 10.1038/ncpendmet0290 17024154 (Pubitemid 44536603)
5. M Filopanti AM Barbieri AR Angioni A Colao V Gasco S Grottoli, et al. 2008 Dopamine D2 receptor gene polymorphism and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas Pharmacogenomics J 8 353 363 10.1038/tpj.2008.1
6. I Pellegrini R Rasolonjanahary G Gunz P Bertrand S Delivet CP Jedynak, et al. 1989 Resistance to bromocriptine in prolactinomas J Clin Endocrinol Met 69 500 509 1:STN:280:DyaL1MzktVOrsA%3D%3D 10.1210/jcem-69-3-500
7. L Caccavelli F Feron I Morange E Rouer R Benarous D Dewailly P Jaquet, et al. 1994 Decrease expression of the two D2 dopamine receptor isoforms in bromocriptin resistant prolactinomas Neuroendocrinology 60 314 322 1:CAS:528:DyaK2cXlvFGhtLw%3D 10.1159/000126764 7969790
8. RN Nawar D AbdelMannan WR Selman BM Arafah 2008 Analytic review: pituitary tumor apoplexy: a review J Intensive Care Med 23 75 90 10.1177/0885066607312992 18372348 (Pubitemid 351442753)
9. BMK Biller ME Molitch ML Vance KB Cannistraro KR Davis JA Simons, et al. 1996 Treatment of prolactin-secreting macroadenomas with once-weekly dopamine agonist cabergoline J Clin Endocrinol Metab 81 2338 2343 1:CAS:528: DyaK28XjsFyktrY%3D 10.1210/jc.81.6.2338 8964874 (Pubitemid 26175965)
10. M Knoepfelmacher MC Gomes ME Melo BB Mendonca 2004 Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma Pituitary 7 83 87 10.1007/s11102-005-5349-x 15761656 (Pubitemid 40372986)
11. A Ishay P Levahar G Qupty 2004 Expansion of intratumoral hemorrhage in a patient with macroprolactinoma treated with cabergoline Endocrinologist 14 126 128 10.1097/01.ten.0000127930.93592.b2 (Pubitemid 38679580)